Pulse Journal Club Active Debates Trending Explore Questions Researchers

Download the App

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

© Synapse Social LLC, 2026

Home Explore Journal Club Trending

⌘+K

Breast Cancer, Version 3.2013 | Synapse

July 1, 2013Open Access

Breast Cancer, Version 3.2013

Key Points

Key points are not available for this paper at this time.

Abstract

These NCCN Guidelines Insights highlight the important updates specific to the management of HER2-positive metastatic breast cancer in the 2013 version of the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer. These include new first-line and subsequent therapy options for patients with HER2-positive metastatic breast cancer.

Mark Helpful

Bookmark

Relay

View Full Paper

Mark Helpful

Bookmark

Relay

View Full Paper

Cite This Study

Theriault et al. (Mon,) studied this question.

synapsesocial.com/papers/6a0252b2dd6c2a8c4fb363dc https://doi.org/https://doi.org/10.6004/jnccn.2013.0098

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1A combination of pertuzumab, trastuzumab, and vinorelbine for first-line treatment of patients with HER2-positive metastatic breast cancer: An open-label, two-cohort, phase II study (VELVET).2012 · 18 citations
2Quality of life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer.2012 · 14 citations
3Semisynthetic Maytansine Analogues for the Targeted Treatment of Cancer2006 · 311 citations
4Abstract S5-1: Biomarker analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC)2012 · 59 citations
5Cancer statistics, 20132013 · 11,899 citations